The truth about Alzheimer’s drugs.

The US Food and Drug Administration (FDA) has recently approved three new drugs for the treatment of early-stage Alzheimer's disease: donanemab, lecanemab, and aducanumab. These drugs are the first to target and remove amyloid proteins, which are believed to be a key factor in the progression of Alzheimer's. However, there are concerns about the safety of these drugs, as they have been associated with side effects such as brain bleeds. While the drugs have shown some effectiveness in slowing cognitive decline, they are not considered a cure for Alzheimer's. Accessing these drugs can be expensive and requires regular brain scans. [Extracted from the article]